Biogen’s Neuroreparative Candidate for MS Flounders in Phase 2 Study

Biogen’s multiple sclerosis candidate opicinumab missed primary endpoints in a Phase 2 study for multiple sclerosis.

Dubbed Anti-LINGO-1, the candidate did not meet a multicomponent endpoint of improvement of ambulation, upper extremity function, cognition and physical disability at three months in 418 participants with relapsing forms of multiple sclerosis.

The neuroreparative therapy also missed a second endpoint that measured the slowing of progression for those components. Biogen plans to analyze the data to inform the design of future studies for the therapy.